Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28149440 | 0.89 | ADORA3 (0.41) | CASP1MEN1KMT2AALDH1A1ADORA2A | |
| SCHEMBL637900 | 0.88 | RAB9A (0.42) | MEN1KMT2AALDH1A1ADORA2ATP53 | |
| SCHEMBL5014126 | 0.84 | RAB9A (0.44) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| Dimethyl Sulfone SCHEMBL17237872 | 0.81 | PTGS2 (0.40) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL27874785 | 0.80 | PARP1 (0.44) | PARP1NPC1RAB9A | |
| SCHEMBL673264 | 0.78 | BCAT2 (0.46) | CASP1MEN1KMT2AALDH1A1MAP2K3 | |
| SCHEMBL27633012 | 0.78 | RAB9A (0.47) | MEN1KMT2AALDH1A1KDM4ELDHA | |
| SCHEMBL28271180 | 0.77 | ENPP3 (0.31) | — | |
| SCHEMBL7237023 | 0.76 | CYP2A6 (0.52) | ALDH1A1KDM4ELMNATP53 | |
| SCHEMBL6135309 | 0.73 | GPR55 (0.39) | ALDH1A1BCAT2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1531810-B1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7507757-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1531810-A4 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20050119312-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2005-06-02 | — | — | US | disclosed |
| EP-1531810-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6875782-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040063762-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004655-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063762-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GLP1R, ZYX, SLC5A2 | CASP1 428/4885MEN1 3516/4885KMT2A 2256/4885 |
| US-20050119312-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | NPY4R, XDH, GPR119 | CASP1 1470/4885MEN1 3510/4885KMT2A 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.